Related Guidance Notes
GNES 12: Recruitment – Is it still about Cultural Fit?
GNES 11: Importance of Autonomy
GNES 10: Employee Wellness Within a Hybrid Working Model
GNES 9: Reinvention during and after COVID- will company culture stand the test of time?
GNES 8: The Importance of Learning Agility
GNES 7: The Good And Bad of Video Interviewing
GNES 6: The importance of direct approach (in executive search)
GNES 5: Creating a company culture that attracts and retains talent during and post-global pandemic
GNES 4: Attracting the right talent in the times of coronavirus – Job Description as a Talent Magnet
GNES 2: Recruit for future-proof profiles
GNES 1: Differences in recruiting for a big pharma and a small biotech
GNL 39: Changes to data exclusivity
GNL37: UK experimental use exemptions
GNL 36: Placing medical devices on the UK market after the end of Brexit transition
GNL 35: What the UK-EU Trade and Cooperation Agreement means for pharma and medical device companies
GNL 21: Licensing manufacturers, wholesale dealers and brokers
GNL 19: Pre-clinical, clinical and post-market surveillance
GNL 15: Keeping Your Confidential Information and Staff Safe From Competition
GNL 14: Medical Devices Regulation – The New Rules
GNL 13: Medical Devices Regulation – The Current Rules
GNL 9: Licensing Patents – Royalties, Warranties & Indemnities and Termination
GNL 8: Licensing Patents – Exclusivity, Territory, Duration and Improvements
GNL 5: Drafting Commercial Agreements – Endeavours and Entire Agreement Clauses, and Contractual Time Bars
GNL 4: Research, Development and Collaboration Agreements
GNT 72: Tax treatment of interest on convertible loans
GNT 71: Corporate Interest Restriction (CIR)
GNT 70: Working from Home (in the UK and abroad) – Common Tax Concerns
GNT 69: Making Tax Digital for Corporation Tax
GNT 68: Making Tax Digital for VAT
GNT 67: Non-resident directors
GNT 65: A tax overview of share schemes and other equity incentives
GNT 64: Off payroll workers : IR35 for the private sector from April 2021
GNT 57: Trading Company Status
GNT 58: Corporate Criminal Offence – As Applied to Life Sciences
GNT 54: PAYE Settlement Agreements (PSAs)
GNT 40: EMI Valuations
GNT 10: EMI Share Options
GNT 31: SME R&D Tax Credit and RDEC Comparison
GNT 27: SME R&D Regime Essentials
GNT 38: Bioscience Explained to Support Tax Returns
GNT 17: Compliance Essentials
GNT 9: Compliance Best Practice for Development Companies
